July 18 (Reuters) - medmix AG MEDX.S :
* IN H1, REVENUE OF CHF 241.2 MILLION, 2.8% LOWER
YEAR-ON-YEAR
* FULL-YEAR 2024 GUIDANCE REDUCED TO REFLECT ONGOING
SOFTNESS IN
END MARKETS
* H1 ADJUSTED EBITDA AT CHF 46.0 MILLION, DECREASE OF -7.4%
YEAR-ON-YEAR
* SEES FY ADJUSTED EBITDA MARGIN OF 18% TO 19% (VERSUS. "AT
LEAST
20%" PREVIOUSLY AND 19.1% ACTUAL IN FY 2023)
* SEES FY ORGANIC REVENUE GROWTH RATE FLAT TO NEGATIVE
(VERSUS.
"+4% TO +6%" PREVIOUSLY AND +1.1% ACTUAL IN FY 2023)
Source text for Eikon: ID:
Further company coverage: MEDX.S
((Reuters.Briefs@thomsonreuters.com;))